Modification and validation of the Birmingham vasculitis activity score (version 3)

Annals of the Rheumatic Diseases

Volumn 68, Issue 12, 2009, Pages 1827-1832

  Mukhtyar, C ^a   Lee, R ^b   Brown, D ^a   Carruthers, D ^c   Dasgupta, B ^d   Dubey, S ^e   Flossmann, O ^f   Hall, C ^b   Hollywood, J ^d   Jayne, D ^f   Jones, R ^f   Lanyon, P ^g   Muir, A ^g   Scott, D ^e   Young, L ^h   Luqmani, R A ^a,b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c CITY HOSPITAL   (United Kingdom)

^d BASILDON HOSPITAL   (United Kingdom)

^e NORFOLK AND NORWICH UNIVERSITY HOSPITAL   (United Kingdom)

^f ADDENBROOKE S HOSPITAL   (United Kingdom)

^g NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^h ROYAL BERKSHIRE NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN;

ADULT; AGED; ARTICLE; BIRMINGHAM VASCULITIS ACTIVITY SCORE; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; PRIORITY JOURNAL; REPRODUCIBILITY; SCORING SYSTEM; SYSTEMIC VASCULITIS; VALIDATION PROCESS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; VASCULITIS; YOUNG ADULT;

EID: 72249087511     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2008.101279     Document Type: Article

References (25)

1. Dubost JJ, Souteyrand P, Sauvezie B. Drug-induced vasculitides. Baillieres Clin Rheumatol 1991;5:119-138
2. Sokoloff L, Wilens SL, Bunim JJ. Arteritis of striated muscle in rheumatoid arthritis. Am J Pathol 1951;27:157-173
3. Gocke DJ, Hsu K, Morgan C, et al. Vasculitis in association with Australia antigen. J Exp Med 1971;134:330s-6s.
4. Jennette JC, Falk RJ, Andrassy K, et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994;37:187-192
5. Del Buono EA, Flint A. Diagnostic usefulness of nasal biopsy in Wegener's granulomatosis. Hum Pathol 1991;22:107-110
6. Devaney KO, Travis WD, Hoffman G, et al. Interpretation of head and neck biopsies in Wegener's granulomatosis. A pathologic study of 126 biopsies in 70 patients. Am J Surg Pathol 1990;14:555-564 (Pubitemid 20172526)
7. Aasarod K, Bostad L, Hammerstrom J, et al. Renal histopathology and clinical course in 94 patients with Wegener's granulomatosis. Nephrol Dial Transplant 2001;16:953-960 (Pubitemid 32440367)
8. Nataraja A, Mukhtyar C, Hellmich B, et al. Outpatient assessment of systemic vasculitis. Best Pract Res Clin Rheumatol 2007;21:713-732
9. Luqmani RA, Bacon PA, Moots RJ, et al. Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. QJM 1994;87:671-678
10. Luqmani RA, Exley AR, Kitas GD, et al. Disease assessment and management of the vasculitides. Baillieres Clin Rheumatol 1997;11:423-446
11. Stone JH, Hoffman GS, Merkel PA, et al. A disease-specific activity index for Wegener's granulomatosis: modification of the Birmingham Vasculitis Activity Score. International Network for the Study of the Systemic Vasculitides (INSSYS). Arthritis Rheum 2001;44:912-920
12. de Groot K, Muhler M, Reinhold-Keller E, et al. Induction of remission in Wegener's granulomatosis with low dose methotrexate. J Rheumatol 1998;25:492-495 (Pubitemid 28109351)
13. Jayne D, Rasmussen N, Andrassy K, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003;349:36-44. (Pubitemid 36765101)
14. Jayne DR, Gaskin G, Rasmussen N, et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol 2007;18:2180-2188 (Pubitemid 47041083)
15. Birck R, Warnatz K, Lorenz HM, et al. 15-Deoxyspergualin in patients with refractory ANCA-associated systemic vasculitis: a six-month open-label trial to evaluate safety and efficacy. J Am Soc Nephrol 2003;14:440-447 (Pubitemid 36150868)
16. Jayne DR, Chapel H, Adu D, et al. Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity. QJM 2000;93:433-439 (Pubitemid 30459921)
17. Hellmich B, Flossmann O, Gross WL, et al. EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis. Ann Rheum Dis 2007;66:605-617 (Pubitemid 46707128)
18. Gayraud M, Guillevin L, le Toumelin P, et al. Long-term followup of polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: analysis of four prospective trials including 278 patients. Arthritis Rheum 2001;44:666-675 (Pubitemid 32234626)
19. Mukhtyar C, Hellmich B, Jayne D, et al. Remission in antineutrophil cytoplasmic antibody-associated systemic vasculitis. Clin Exp Rheumatol 2006;24:S93-8.
20. Flossmann O, Bacon P, de Groot K, et al. Development of comprehensive disease assessment in systemic vasculitis. Ann Rheum Dis 2007;66:283-292
21. Jayne DR, Gaskin G, Pusey CD, et al. ANCA and predicting relapse in systemic vasculitis. QJM 1995;88:127-133
22. Reinhold-Keller E, Beuge N, Latza U, et al. An interdisciplinary approach to the care of patients with Wegener's granulomatosis: long-term outcome in 155 patients. Arthritis Rheum 2000;43:1021-1032
23. Misra R, Danda D, Jayaseelan L, et al. ITAS and DEI.TAK - Scores for clinical disease activity and damage extent in Takayasu aortoarteritis (TA). Rheumatology (Oxford) 2008;47:ii101.
24. Leavitt RY, Fauci AS. Less common manifestations and presentations of Wegener's granulomatosis. Curr Opin Rheumatol 1992;4:16-22.
25. Leavitt RY, Fauci AS. Polyangiitis overlap syndrome. Classification and prospective clinical experience. Am J Med 1986;81:79-85.